JIANGSU KANION PHARMACEUTICAL CO.，LTD．

The company is a large traditional Chinese medicine enterprise integrating drug research and development, production, and sales. It is a national key high-tech enterprise, a national technological innovation demonstration enterprise, China's top 100 pharmaceutical industry enterprises (29th), fifth in the top ten Chinese medicine enterprises in the country, and the top 20 innovative Chinese pharmaceutical companies. It has built a number of national research platforms such as the “State Key Laboratory for New Technology in Traditional Chinese Medicine Pharmaceutical Processes”. In 2018, the laboratory was awarded the “State Key Laboratory of Outstanding Enterprises” (No. 1 in the pharmaceutical field). The main business involves R&D, production and sales of pharmaceuticals. The company's main product line currently focuses on traditional Chinese medicine advantage areas such as respiratory and infectious diseases, gynecological diseases, cardiovascular diseases, and orthopedic diseases. Representative varieties of the respiratory and infectious disease product line include Jin Zhen oral solution, hepatocin injection, apricot shell cough tablets, cooling and humidification granules, silver kiao cleansing tablets, yingqiao detoxifying softgels, etc.; representative varieties of the gynecological product line include guizhi poria capsules, dispersion analgesia capsules, etc.; representative varieties of the cardiovascular product line include ginkgo biloba diterpene glucamine injections (Tianshu capsules) Tablets), Dragon Blood Tongluo capsules, Tongsai tablets, Yixin tablets, Dazhu Rhodiola capsules, Cistanche total glycosides Capsules, etc.; Representative varieties of orthopedic product lines include Compound Nanxing Pain Relief Cream, Lumbar Pain Relief Capsule, Musculoskeletal Pain Relief Gel, Shichimi Pain Relief Oral Liquid, and Agastache Total Flavonoid Capsules. The company is a national technological innovation demonstration enterprise, a national key high-tech enterprise, a national innovative pilot enterprise, a national intellectual property demonstration enterprise, and one of the top 100 enterprises in the national pharmaceutical industry.